MK0974 Ethanolate formulation
DrugSingle dose MK0974 280 mg tablet in one of two treatment periods
NCT Number: NCT00965887
This study will evaluate the bioequivalence of two solid dose formulations of MK0974.
Looking for future studies?
Notify Me18 year–55 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Single dose MK0974 280 mg tablet in one of two treatment periods
Single dose MK0974 280 mg tablet in one of two treatment periods
Time frame: Through 48 hours postdose
Time frame: Through 48 Hours Post Dose
Merck Sharp & Dohme LLC
Industry
An Open-Label, Randomized, 2-Period Crossover Study to Evaluate the Bioequivalence of a Single Dose of a Tablet Form of MK0974 Ethanolate vs. a Single Dose of a Tablet Form of MK0974 Hydrate in Healthy Subjects
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04530110
Brain Diseases, Central Nervous System Diseases
Aurora, Colorado, United States
View Trial DetailsNCT07699549
Brain Diseases, Central Nervous System Diseases
Madrid, Spain
View Trial DetailsNCT07720895
Brain Diseases, Central Nervous System Diseases
Athens, Greece
View Trial DetailsNCT06158737
Brain Diseases, Central Nervous System Diseases
Beijing, Beijing Municipality, China
View Trial Details